Clinical Trial Update: CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing CP-675,206 with dacarbazine or temozolomide in previously untreated melanoma patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CP-675,206
• Dacarbazine (dacarbazine)
• Temozolomide (Temozolomide)

Snippet

Sponsor: AstraZeneca | Conditions: Melanoma | Phase 3 | Status: COMPLETED